Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.
about
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in KoreaCritical appraisal of eculizumab for atypical hemolytic uremic syndromeEscherichia coli induces platelet aggregation in an FcγRIIa-dependent manner.Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab.Complement in disease: a defence system turning offensiveMonitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.HUS and atypical HUS.Atypical Hemolytic Uremic Syndrome: A Brief Review.Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.Complement Activation in Placental Malaria.Necroinflammation in Kidney Disease.Treatment of catastrophic antiphospholipid syndromeMaintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literatureDangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation.Endothelial cells: source, barrier, and target of defensive mediators.Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.[Hemolytic anemia].Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?The Complement System and Preeclampsia.Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.Pregnancy-induced atypical haemolytic uremic syndrome: A new era with eculizumab.The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome.Atypical hemolytic uremic syndrome and eculizumab therapy in children.
P2860
Q26739894-15092DCD-BA81-45C4-A219-709DFD5C87EFQ26750692-DDB1CEBD-EFC0-44AD-B0B3-C1ADB3A9EAB3Q33428410-2C21A8A2-EDFB-473C-8E14-0E92DBCB539BQ33430038-7D26C46E-9129-4183-9C61-7FAE0BD54598Q33432423-F5561577-C5B5-40CB-AB22-88C735F19AF8Q33436307-5A2B4924-5326-46BB-ACCE-84B1E1CD8A30Q33441069-5F2C2578-1DBA-44A8-B6DC-CF9EBEA51BC2Q33442794-1DC29D14-65C5-4237-9493-03E8CADBF6C7Q33783126-7C9830A9-7918-47F8-A6DA-2D38071088EBQ36387332-47E17AD4-1F61-4B5E-BD3D-BE0AB95B9454Q38579499-32475820-4BB4-4407-828A-B621EDABE0C8Q38755260-87B4CC6E-85DA-4FFC-A272-3E3FA4C75F3CQ38927860-23005E37-EE1F-4542-90F3-D351B2778B3AQ38991010-B293CD04-095E-4FCB-BE8B-4F9DFD141E5EQ38991026-47D5E5A1-0D83-4218-9A9E-FFBB923E71E8Q39229604-7CE00F86-AEC2-4467-B2C8-3075AA3382B9Q41070320-CFA423A0-0619-47BA-8067-9D958078371DQ42000134-D1B8F17C-EEED-41BD-82D0-7F6AE7D75223Q47889401-FBAFBECF-FEAA-450A-A0F9-7D0143BD99F3Q48102410-60EB4101-49E5-433E-B962-AF9C8F427EF5Q48114152-3C7914A2-8E32-4FF9-BE34-81FBDCE41AC1Q50660833-714348ED-2D78-49D8-A4D0-984D7AA4D0CAQ52595152-BCEE01D6-FB89-4664-80C3-B51FAAFFE5DEQ52767922-7B34F616-8E12-440F-863D-925841A2089DQ54207419-0C66807A-6079-42D0-B793-BC8AEDC76AB1
P2860
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Eculizumab reduces complement ...... renal injury markers in aHUS.
@ast
Eculizumab reduces complement ...... renal injury markers in aHUS.
@en
type
label
Eculizumab reduces complement ...... renal injury markers in aHUS.
@ast
Eculizumab reduces complement ...... renal injury markers in aHUS.
@en
prefLabel
Eculizumab reduces complement ...... renal injury markers in aHUS.
@ast
Eculizumab reduces complement ...... renal injury markers in aHUS.
@en
P2093
P2860
P1433
P1476
Eculizumab reduces complement ...... renal injury markers in aHUS.
@en
P2093
Angela P Mickle
Anjli Kukreja
Camille L Bedrosian
Krystin Bedard
Masayo Ogawa
Roxanne Cofiell
Susan J Faas
P2860
P304
P356
10.1182/BLOOD-2014-09-600411
P407
P577
2015-04-01T00:00:00Z